Drug Profile
Palupiprant - Adlai Nortye
Alternative Names: AN-0025; E-7046; TPST-7317Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator Eisai Inc
- Developer Adlai Nortye; Eisai Inc
- Class Amides; Antineoplastics; Benzoic acids; Fluorinated hydrocarbons; Phenyl ethers; Pyrazoles; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder cancer; Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Triple negative breast cancer
Most Recent Events
- 05 Oct 2023 Palupiprant is still in phase I trials for Triple-negative-breast-cancer, Colorectal cancer, Cervical cancer, Non-small cell lung cancer, Rectal cancer, Bladder cancer in USA, France, Poland, United Kingdom (PO) (Adlai Nortye pipeline, September 2023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Cervical-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)